Other drug therapy

Source: Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 19, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome / Treatment Options for Stage III and Stage IV Mycosis Fungoides and Sézary Syndrome

Symptomatic management with topical corticosteroids. Low potency steroids can be used on the face with safety and efficacy.[43]

Source links and citations

Lenalidomide.[44]

Source links and citations

Bexarotene, an oral or topical retinoid.[45,46]

Source links and citations

Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[2,47-49]

Source links and citations

Vorinostat or romidepsin or other histone deacetylase inhibitors (HDACi).[2,47-49]

A retrospective review of 198 patients with mycosis fungoides and Sézary syndrome compared TTNT between HDACi and conventional chemotherapy. HDACi provided a longer TTNT of 4.5 months (95% CI, 4.0–6.1) than did chemotherapy, with a TTNT of 3.9 months (95% CI, 3.2–5.1; P = .01).[29][Level of evidence C3]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice